EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Trastuzumab Deruxtecan‐Induced Myotoxicity: First Case Report About Myopathy in Patient With Normal Body Composition and Clinical Insights

Zhen Qiao, LiuDan Li, Hong Wang, ShuHui Dai, LiTong Ye

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.70168 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Zhen Qiao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Zhuhai Center For Maternal and Child Health Care (Zhuhai Women and Children's Hospital), Zhuhai, China. Hauptthemen laut MEDLINE: Trastuzumab, Myotoxicity, Breast Neoplasms, Muscular Diseases. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 2023 Zhuhai Medical Research Project, Zhuhai Science and Technology Plan Project in the Field of Social Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trastuzumab deruxtecan (T‐DXd) significantly improves outcomes in HER2‐positive or low metastatic breast cancer (MBC), but systematic documentation of its myotoxicity is lacking. A 45‐year‐old woman with HER2‐low MBC and normal body composition (BMI 22.9 kg/m 2 , visceral adipose area [VAT] 69.1 cm 2 ) developed T‐DXd myopathy. She experienced dysphagia, Grade III myalgia, and creatine kinase (CK) peak of 1755 U/L, with MRI confirming lumbar subcutaneous edema and paraspinal muscle swelling. T‐DXd was discontinued. Supportive therapy included hydration, urine alkalization by sodium bicarbonate, glutathione, and magnesium isoglycyrrhizinate. By Day 8, CK decreased to 539 U/L with myalgia improvement. After 13 days off therapy, CK rebounded to 1735 U/L with Grade III myalgia, which resolved upon reinitiating support. This case report presents the first documented instance of severe T‐DXd‐related myopathy in a patient with normal body composition. The observed case outcomes suggest that the combination of glutathione and magnesium isoglycyrrhizinate could potentially reduce CK levels and alleviate T‐DXd‐associated muscle pain. However, the observed clinical efficacy is based on an individual case. Extrapolation of these clinical outcomes requires large‐scale randomized controlled trials with rigorous covariate adjustment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabMyotoxicityBreast NeoplasmsMuscular DiseasesAntineoplastic Agents, ImmunologicalHumansFemaleMiddle AgedBody Composition

Stichwörter der Autor:innen

creatine kinaseglutathionemagnesium isoglycyrrhizinatemyotoxicitytrastuzumab deruxtecan

Substanzen

TrastuzumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Breast Surgery, Zhuhai Center For Maternal and Child Health Care (Zhuhai Women and Children's Hospital), Zhuhai, China.
  • Department of Nursing, Zhuhai Center For Maternal and Child Health Care (Zhuhai Women and Children's Hospital), Zhuhai, China.
  • Hospital Infection Control Department, Zhuhai Center For Maternal and Child Health Care (Zhuhai Women and Children's Hospital), Zhuhai, China.

Förderung

  • 2023 Zhuhai Medical Research Project
  • Zhuhai Science and Technology Plan Project in the Field of Social Development

Zitieren

APA

Qiao, Z., Li, L., Wang, H., Dai, S., & Ye, L. (2025). Trastuzumab Deruxtecan‐Induced Myotoxicity: First Case Report About Myopathy in Patient With Normal Body Composition and Clinical Insights. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70168

Vancouver

Qiao Z, Li L, Wang H, Dai S, Ye L. Trastuzumab Deruxtecan‐Induced Myotoxicity: First Case Report About Myopathy in Patient With Normal Body Composition and Clinical Insights. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70168

BibTeX
@article{Qiao2025,
  author = {Qiao, Zhen and Li, LiuDan and Wang, Hong and Dai, ShuHui and Ye, LiTong},
  title = {Trastuzumab Deruxtecan‐Induced Myotoxicity: First Case Report About Myopathy in Patient With Normal Body Composition and Clinical Insights},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.70168}
}
Kostenlos starten →